191 related articles for article (PubMed ID: 30416173)
1. Intraocular lymphoma as relapse after chemotherapy for primary breast diffuse large B-cell lymphoma.
Matsuo T; Tanaka T; Yano T
J Clin Exp Hematop; 2018 Dec; 58(4):180-183. PubMed ID: 30416173
[No Abstract] [Full Text] [Related]
2. Hidden superpower.
McGuirt J
JAAPA; 2019 May; 32(5):66. PubMed ID: 31033720
[No Abstract] [Full Text] [Related]
3. Hope for very elderly patients with diffuse large B-cell lymphoma.
Ribera JM
Lancet Oncol; 2011 May; 12(5):412-3. PubMed ID: 21482185
[No Abstract] [Full Text] [Related]
4. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
Musolino A; Boggiani D; Panebianco M; Vasini G; Salvagni S; Franciosi V; Ardizzoni A
Cancer; 2011 Mar; 117(5):964-73. PubMed ID: 20960528
[TBL] [Abstract][Full Text] [Related]
5. Metabolic tumour volume and response to therapy in diffuse large B-cell lymphoma.
Campiotti L; Suter MB; De Palma D; Proserpio I; Uccella S; Squizzato A
Hematol Oncol; 2019 Aug; 37(3):308-309. PubMed ID: 30933368
[No Abstract] [Full Text] [Related]
6. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
7. High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance).
Witzig TE; LaPlant B; Habermann TM; McPhail E; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Johnston PB
Blood Cancer J; 2017 Jun; 7(6):e576. PubMed ID: 28649983
[No Abstract] [Full Text] [Related]
8. Large gastrosplenic fistula after effective treatment of abdominal diffuse large-B-cell lymphoma.
Palmowski M; Zechmann C; Satzl S; Bartling S; Hallscheidt P
Ann Hematol; 2008 Apr; 87(4):337-8. PubMed ID: 17929016
[No Abstract] [Full Text] [Related]
9. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
[TBL] [Abstract][Full Text] [Related]
10. Abnormal positron emission tomography (PET) scan secondary to the use of hematopoietic growth factors.
Johnston KL; Farnen JP; Manske BR; Go RS
Haematologica; 2005 Dec; 90(12 Suppl):EIM03. PubMed ID: 16464762
[No Abstract] [Full Text] [Related]
11. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
Schmitz N; Zeynalova S; Nickelsen M; Kansara R; Villa D; Sehn LH; Glass B; Scott DW; Gascoyne RD; Connors JM; Ziepert M; Pfreundschuh M; Loeffler M; Savage KJ
J Clin Oncol; 2016 Sep; 34(26):3150-6. PubMed ID: 27382100
[TBL] [Abstract][Full Text] [Related]
12. Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.
Ganti A; Liu W; Luo S; Sanfilippo KM; Roop R; Lynch R; Riedell P; O'Brian K; Colditz GA; Carson KR
Br J Haematol; 2014 Dec; 167(5):699-702. PubMed ID: 25040880
[No Abstract] [Full Text] [Related]
13. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
14. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
15. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
[TBL] [Abstract][Full Text] [Related]
16. [Supportive care for patients with non-Hodgkin lymphoma receiving R-CHOP chemotherapy].
Kato H
Nihon Rinsho; 2015 Feb; 73 Suppl 2():636-41. PubMed ID: 25831838
[No Abstract] [Full Text] [Related]
17. Locally distributed multicentric plasmacytomas in the ileum secondary to lymphoma chemoimmunotherapy.
Yokoo M; Kojima K; Sano H; Kai K; Arakawa F; Ohshima K; Matsunaga T; Kimura S
Ann Hematol; 2019 Jun; 98(6):1501-1503. PubMed ID: 30406822
[No Abstract] [Full Text] [Related]
18. Quality of life research: adding an important dimension to the evaluation of therapeutic outcomes.
Hamilton AS
Leuk Lymphoma; 2011 Mar; 52(3):353-4. PubMed ID: 21323516
[No Abstract] [Full Text] [Related]
19. Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma.
Arakaki H; Nakazato T; Osada Y; Ito C; Aisa Y; Mori T
Ann Hematol; 2017 Jul; 96(7):1225-1226. PubMed ID: 28508175
[No Abstract] [Full Text] [Related]
20. A Host-Dependent Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma.
Miura K; Konishi J; Miyake T; Makita M; Hojo A; Masaki Y; Uno M; Ozaki J; Yoshida C; Niiya D; Kitazume K; Maeda Y; Takizawa J; Sakai R; Yano T; Yamamoto K; Sunami K; Hiramatsu Y; Aoyama K; Tsujimura H; Murakami J; Hatta Y; Kanno M
Oncologist; 2017 May; 22(5):554-560. PubMed ID: 28408622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
